Omalizumab treatment in severe adult atopic dermatitis.

Simple item page
dc.contributor.authorThaiwat, Supitchaya
dc.contributor.authorSangasapaviliya, Atik
dc.date.accessioned2012-01-12T09:43:06Z
dc.date.available2012-01-12T09:43:06Z
dc.date.issued2011-12
dc.description.abstractAtopic dermatitis (AD) is one of the most common chronic skin diseases. Treatment options include lubricants, antihistamines, and corticosteroids in either topical or oral forms. Severe AD is frequently recalcitrant to these medications. We reported three cases of severe AD patients who had elevated of IgE levels and failed to response to several prior medical treatment. After being treated with Omalizumab (humanized monoclonal anti-IgE antibody), the patients had marked alleviation of symptoms with improved Eczema Area and Severity Index (EASI) and pruritic scores. No patient experienced adverse effect.en_US
dc.identifier.citationThaiwat Supitchaya, Sangasapaviliya Atik. Omalizumab treatment in severe adult atopic dermatitis. Asian Pacific Journal of Allergy and Immunology, 2011 Dec; 29(4): 357-360.en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/136437
dc.language.isoenen_US
dc.source.urihttps://apjai.digitaljournals.org/index.php/apjai/article/viewFile/855/789en_US
dc.subjectOmalizumaben_US
dc.subjectIgE levelsen_US
dc.subjectEASI scoreen_US
dc.titleOmalizumab treatment in severe adult atopic dermatitis.en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
apjai2011v29n4p357.pdf
Size:
239.21 KB
Format:
Adobe Portable Document Format
Description:
Journal article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Asian Pacific Journal of Allergy and Immunology